ArticleJournal of diabetes research2026
A Study of the Relationship Between Serum Albumin-Corrected Fructosamine and Type 2 Diabetic Retinopathy.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine the association between albumin-corrected fructosamine (AlbF) levels and the presence of diabetic retinopathy (DR) in adults with Type 2 diabetes mellitus (T2DM). Methods: This cross-sectional study retrospectively analyzed 1263 inpatients with T2DM. After applying exclusion criteria, 415 patients were included and categorized into DR ( Results: The prevalence of DR was 41.9%. Following full adjustment, each 10 Conclusions: Elevated AlbF was independently associated with the presence of DR in adults with T2DM, demonstrating a significant dose-response relationship. AlbF shows promise as a biomarker candidate for DR identification and stratification. Its potential clinical utility requires validation in larger prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.